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Abstract Arsenic trioxide (As2O3) inhibits cell growth and
induces apoptosis in certain types of cancer cells including acute
promyelocytic leukemia, prostate and ovarian carcinomas, but its
effect on response of tumor cells to ionizing radiation has never
been explored before. Here we demonstrate that As2O3 can
sensitize human cervical cancer cells to ionizing radiation both in
vitro and in vivo. As2O3 in combination with ionizing radiation
have a synergistic effect in decreasing clonogenic survival and in
the regression of established human cervical tumor xenografts.
Pretreatment of the cells with As2O3 also synergistically
enhanced radiation-induced apoptosis. Apoptosis of the cells by
combined treatment of As2O3 and radiation was associated with
reactive oxygen species generation and loss of mitochondrial
membrane potential, resulting in the activation of caspase-9 and
caspase-3. The combined treatment also resulted in an increased
G2/M cell cycle distribution at the concentration of As2O3 which
did not alter cell cycle when applied alone. These results indicate
that As2O3 can synergistically enhance radiosensitivity of human
cervix carcinoma cells in vitro and in vivo, suggesting a potential
clinical applicability of combination treatment of As2O3 and
ionizing radiation in cancer therapies. ) 2002 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Cervical cancer is one of the most common cancers, ac-
counting for almost 6% of all malignancies in women. Each
year, there are an estimated 16 000 new cases of invasive can-
cer of the cervix and 5000 deaths in the United States. World-
wide, cervical cancer is second only to breast cancer as the
most common malignancy in both incidence and mortality [1].
Arsenic agents have been used as anti-cancer agents in tra-
ditional Chinese medicine [2]. The clinical e⁄cacy of arsenic
trioxide (As2O3) in acute promyelocytic leukemia (APL) has
been con¢rmed even in patients resistant to conventional che-
motherapy [3,4]. As2O3 is recently reported to be an e¡ective
inducer of apoptosis in certain cancer cells including APL,
other myeloid leukemic cells, esophageal, prostate and ovar-
ian carcinomas [5,6,7]. Although the mechanism for the in-
duction of apoptosis has not fully been characterized, several
studies demonstrated that As2O3 might be an oxidative agent
that induced DNA damage and caused apoptosis [8,9]. Evi-
dences also indicate that As2O3 induces apoptosis in leukemia
and melanoma cells by modulating expression of Bcl-2 protein
family [10,11], or by activating caspases [12,13].
One of the important points in the development of a new
anti-cancer drug is the understanding of its potential for in-
clusion in combination treatment regimens. Recent studies
demonstrated additive e¡ects of As2O3 with conventional che-
motherapeutic agents such as cisplatin, adriamycin, and eto-
poside, but no synergism [5,14]. On the other hand, the com-
bined e¡ect of As2O3 on response of cancer cells to ionizing
radiation (IR) has never been examined before. In the present
study, we demonstrated for the ¢rst time that As2O3 sensitize
human cervix carcinoma cells to IR, suggesting that combi-
nation treatment of As2O3 with IR may be a new and more
e¡ective means of cancer treatment.
2. Materials and methods
2.1. Cell culture
HeLa human cervical carcinoma was obtained from the American
Type Culture Collection (Rockville, MD, USA). Cells were grown in
RPMI 1640 medium supplemented with 10% fetal bovine serum, pen-
icillin and streptomycin.
2.2. Materials
Arsenic trioxide (As2O3) was obtained from Sigma. Polyclonal anti-
bodies to caspase-3 and poly ADP-ribose polymerase (PARP) were
purchased from Cell Signaling Technology, and caspase-9 was ob-
tained from Santa Cruz.
2.3. Clonogenic survival assay
Cells were seeded into 60-mm dishes at a density to produce ap-
proximately 200 colonies per dish in the controls and were incubated
for 10^14 days. Colonies were ¢xed with 75% ethanol and 25% acetic
acid, and stained with trypan blue. The number of colonies consisting
of more than 50 cells was counted.
2.4. Flow cytometric analysis of apoptosis
Apoptosis was identi¢ed and quanti¢ed by £ow cytometry with
propidium iodide (PI) staining. Both adherent and £oating cells
0014-5793 / 02 / $22.00 J 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 2 7 6 5 - 5
*Corresponding author. Fax: (82)-2-970-0381.
E-mail address: sjlee@mail.kcch.re.kr (S.-J. Lee).
1 These authors contributed equally to this work.
Abbreviations: APL, acute promyelocytic leukemia; ROS, reactive
oxygen species; DCFH-DA, 2P,7P-dichloro£uorescin diacetate;
NAC, N-acetylcysteine; PARP, poly ADP-ribose polymerase
FEBS 26121 13-5-02
FEBS 26121 FEBS Letters 519 (2002) 195^200
were collected 24 or 48 h after the di¡erent regimen treatment, washed
with ice-cold PBS and ¢xed with 70% ice-cold ethanol overnight at
4‡C. Fixed cells were washed twice with PBS and treated with 1 mg/ml
RNase for 30 min at 37‡C. Cellular DNA was stained with 50 Wg/ml
PI in PBS containing 0.05% Nonidet P-40. Cells were then analyzed
by FACScan £ow cytometer (Becton Dickinson, Franklin Lakes, NJ,
USA). From the analysis of DNA histograms, the percentage of cells
in di¡erent cell cycle phases was evaluated. Cells with DNA content
less than the cells in the G1 phase (sub-G1) were taken as apoptotic
cells.
To determine cell death was attributable to apoptosis, whole cells
were stained with FITC-conjugated Annexin V (Pharmingen) and PI
according to manufacturer’s protocol. Cells were then analyzed by
FACScan £ow cytometer (Becton Dickinson, Franklin Lakes, NJ,
USA).
2.5. Western blot analysis
Cell lysates were prepared by extracting proteins with lysis bu¡er
[40 mM Tris^HCl (pH 8.0), 120 mM NaCl, 0.1% Nonidet-P40] sup-
plemented with protease inhibitors. Proteins were separated by SDS^
PAGE and transferred to nitrocellulose membrane. The membrane
was blocked with 5% non-fat dry milk in Tris-bu¡ered saline and
then incubated with primary antibodies for 1 h at room temperature.
Blots were developed by peroxidase-conjugated secondary antibody,
and proteins were visualized by enhanced chemiluminescence proce-
dures (NEN) according to the manufacturer’s recommendation.
2.6. Fluorescent measurement of intracellular reactive oxygen species
(ROS)
The £uorescent probe 2P,7P-dichloro£uorescin diacetate (DCFH-
DA) was used for the assessment of intracellular ROS. For £uorocy-
tometrical analysis, cells were plated in 60-mm dishes (1U105 cells/
dish) and loaded for 30 min at room temperature with 10 WM DCFH-
DA in 5 ml PBS. Unincorporated DCFH-DA was removed by two
washes in PBS. DCFH-DA-loaded cells were stimulated with As2O3
or radiation alone, or in combination. Fluorescence was measured
using a £ow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
2.7. Measurement of mitochondrial membrane potential
Mitochondrial membrane potential was determined as the retention
Fig. 1. Radiosensitizing e¡ect of As2O3 in vitro and in vivo. A: Cells were treated with various concentrations of As2O3 and irradiated with in-
creasing doses of Q-radiation 1 h after drug addition. Cells were allowed to grow for 10^14 days and were stained with trypan blue and scored
for colony formation. Results are given as meansRS.D. of three independent experiments. B: Exponentially growing HeLa cells were injected
into the hind leg of nude mice. Treatment with As2O3 (3U20 mg/kg) alone, Q-radiation (1U7.5 Gy) alone or combination with As2O3 and Q-ra-
diation (3U20 mg/kg of As2O3 combined with 1U7.5 Gy of Q-radiation) was started after tumor reached a minimal volume of 120 mm3.
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of the mitochondria-speci¢c dye DiO6(3). Cells were loaded with 30
nM DiO6(3) during the last 30 min of radiation and/or As2O3 treat-
ment. After removal of the medium, the cells were washed twice with
PBS, and the concentration of retained DiO6(3) was measured using
£ow cytometer (Beckton Dickinson, Franklin Lakes, NJ, USA).
2.8. Tumor xenografts in nude mice
Human cervix carcinoma cells (HeLa) were injected into the hind
leg of 5^6 week old athymic nude mice, and tumor volumes were
determined according to the formula (LUl2)/2 by measuring tumor
length (L) and width (l) with a caliper.
Fig. 2. Enhancement of IR-induced apoptosis by As2O3. Cells were treated with As2O3 alone (1 or 2 WM), Q-radiation alone (4 Gy) or combi-
nation of both As2O3 and Q-radiation (1 or 2 WM of As2O3 combined with 4 Gy of Q-radiation). A: After 48 h, apoptosis was determined by
Annexin V staining (left) and £ow cytometric analysis after PI staining (right). The data represent average values of triplicate experiments with
standard deviation. B: To analyze DNA ladder formation, the DNAs were extracted from cells as described in Section 2. The DNAs were sub-
jected to agarose gel electrophoresis, stained with ethidium bromide and visualized under UV light. A representative of three independent ex-
periments is shown. C: Cells were incubated with 30 nM DiO6(3) during the last 30 min of treatment. Forty-eight hours after treatment, the
amount of retained DiO6(3) was measured with £ow cytometry. The data represent average values of triplicate experiments with standard devi-
ation. D: After 48 h, cell lysates were prepared and Western blot analysis was performed using anti-cytochrome c, caspase-9, caspase-3 and
PARP antibodies. The data represent a typical experiment conducted three times with similar results.
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3. Results and discussion
3.1. Radiosensitizing e¡ect of As2O3 in vitro
Earlier studies demonstrated an additive e¡ect of As2O3
on apoptosis induced by chemotherapeutic agents such as
cisplatin, adriamycin and etoposide in certain types of cancer
[5,14]. In the present study, employing human cervix carci-
noma cells, clonogenic survival assays were performed with
increasing doses (0.5, 1, 2, 3 or 4 Gy) of IR alone and in
combination with increasing concentration of As2O3 (0.1,
0.5, 1 or 2 WM). As shown in Fig. 1A, clonogenic survival
of HeLa cells was synergistically reduced, when IR treatment
was combined with As2O3. The pretreatment of cells with
As2O3 alone did not signi¢cantly a¡ect clonogenic survival
at the dose levels of 0.1 and 0.5 WM, however As2O3 in
combination with IR synergistically reduced clonogenic sur-
vival. The cooperative e¡ect of As2O3 and IR was further
enhanced when higher concentrations of As2O3 were applied,
resulting in reduced clonogenic survival. Similar radiosensi-
tizing e¡ects by pretreatment with As2O3 (1 or 2 WM) were
also observed in other human cervical cancer cell lines such
as HeLa229 and CaSki (Fig. 1A). These data indicate that
As2O3 can sensitize human cervical cancer cells to IR in
vitro.
3.2. Radiosensitizing e¡ect of As2O3 on tumor xenografts
To determine whether the in vitro e¡ects of As2O3 can be
extended to an in vivo xenografts model, the e¡ect of com-
bined treatment of As2O3 and IR was tested in vivo against
tumor derived from HeLa cells injected into the hind leg of
nude mice. Treatment with locoregional application of IR
using a shielding device at a single dose of 7.5 Gy was started
when tumors reached a minimal size of 130 mm3 R 10% (days
14^18 after cell injection). Fig. 1B shows the e¡ect of treat-
Fig. 3. Combined e¡ect of As2O3 and IR on production of ROS. A: HeLa cells were loaded with DCFH-DA and further stimulated with
As2O3 alone (2 WM), Q-radiation alone (4 Gy) or combination of both As2O3 and Q-radiation (2 WM of As2O3 combined with 4 Gy of Q-radia-
tion) in the presence or absence of NAC. After 48 h, £uorescence was measured using £ow cytometry. B: Cells were treated with As2O3 alone
(2 WM), Q-radiation alone (4 Gy) or combination of both As2O3 and Q-radiation (2 WM of As2O3 combined with 4 Gy of Q-radiation) in the
presence or absence of NAC. After 48 h, cells were stained with Annexin V-FITC. Fluorescence was measured using £ow cytometry. The data
represent average values of three independent experiments with standard deviation. C: Cells were treated with As2O3 alone (2 WM), Q-radiation
alone (4 Gy) or combination of both As2O3 and Q-radiation (2 WM of As2O3 combined with 4 Gy of Q-radiation) in the presence or absence of
NAC. Cells were incubated with 30 nM DiO6(3) during the last 30 min of treatment. After 48 h, the amount of retained DiO6(3) was measured
with £ow cytometry. The data represent average values of triplicate experiments with standard deviation.
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ment of tumors with As2O3 (3U20 mg/kg) alone, Q-radiation
(1U7.5 Gy) alone, and in combination (3U20 mg/kg As2O3
combined with Q-radiation 1U7.5 Gy). Treatment with As2O3
or Q-radiation alone resulted in a partial tumor growth delay,
whereas combined treatment with As2O3 increased the anti-
tumor e¡ect of IR, which resulted in extended tumor growth
delay.
3.3. Enhancement of radiation-induced apoptosis by As2O3
We next investigated whether the reduced clonogenic sur-
vival by combined treatment of As2O3 and Q-radiation was
associated with induction of apoptosis. Therefore, Annexin
V staining, £ow cytometric cell death analysis and DNA lad-
dering were performed to evaluate the extent of apoptosis. As
seen in Fig. 2A, pretreatment with As2O3 at 1 WM concen-
tration, which induced only minimal apoptotic e¡ect (less
than 5%), synergistically enhanced IR-induced apoptosis.
The combined e¡ect of As2O3 and IR was further enhanced,
when an increased concentration of As2O3 (2 WM) was ap-
plied. The extent of apoptosis of HeLa cells in response to the
di¡erent regimen treatment was further con¢rmed by DNA
laddering analysis (Fig. 2B): cells were treated with As2O3 (2
WM) in combination with IR (4 Gy) and were analyzed for
DNA laddering formation 48 h after the treatment. Taken
together, these results demonstrate that As2O3 augments ap-
optotic cell death of human cervical cancer cells in response to
the IR.
3.4. Loss of mitochondrial membrane potential and caspase
activation are involved in As2O3-induced radiosensitization
To assess the induction of apoptosis at the biochemical
level, changes in mitochondrial membrane potential, activa-
tion of caspase-9, the initiator caspase, and caspase-3, the
major e¡ector caspase of the apoptotic machinery, were de-
termined after treatment with As2O3 alone, IR alone or in
combination. Treatment with 2 WM As2O3 alone decreased
DiO6(3) retention, which re£ects loss of mitochondrial mem-
brane potential. The loss of mitochondrial membrane poten-
tial was further enhanced by the combined treatment with
As2O3 and radiation (Fig. 2C). We also observed enhanced
activation of caspase-9 and caspase-3, and PARP cleavage on
treatment with As2O3 in combination with radiation com-
pared to the groups treated with either reagent alone (Fig.
2D). These ¢ndings suggest that Q-radiation in combination
with As2O3 modulates caspase-3 activity following the loss of
mitochondrial membrane potential, thereby enhancing apo-
ptotic cell death.
3.5. Combined e¡ect of As2O3 and IR on ROS generation
Recently, the generation of ROS has been shown to regu-
late As2O3-induced apoptosis [15^17]. To investigate the rela-
tionship between ROS production and enhancement of radi-
ation-induced apoptosis by As2O3, the ROS-sensitive dye
DCFH-DA was used in the £ow cytometric analysis to detect
ROS generation (Fig. 3A). The production of ROS was syn-
ergistically induced by the combined treatment of As2O3 and
IR even at doses that induce minimal ROS generation upon
treatment with either reagent alone. N-acetylcysteine (NAC)
which is a well known inhibitor of ROS completely protected
HeLa cells from apoptosis as well as ROS generation induced
by the combined treatment (Fig. 3A,B). NAC also attenuated
the loss of mitochondrial membrane potential (Fig. 3C) and
caspase-3 activation (data not shown). These results indicate
that ROS generated by combined treatment of As2O3 and IR
regulates apoptotic process including intracellular caspase sig-
naling.
Fig. 4. As2O3 enhances IR-mediated increase of G2/M distribution. Cells were treated with As2O3 alone (1 or 2 WM), Q-radiation alone (4 Gy)
or combination of both As2O3 and Q-radiation (1 or 2 WM of As2O3 combined with 4 Gy of Q-radiation). At times indicated, cells were har-
vested and subjected to £ow cytometric analysis to determine cell cycle distribution.
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3.6. As2O3 enhances IR-mediated increased G2/M distribution
In addition to apoptosis, As2O3 and IR can also modulate
cell cycle progression. Therefore, we examined cell cycle alter-
ations as an another possible explanation for the observed
cooperative e¡ect on the clonogenic cell survival. As shown
in Fig. 4, IR alone induced accumulation of cells at G2/M
phase on 12 h after radiation and cells then resume cell cycle
progression after 24 h. At the concentration of 1 WM As2O3
which, had no e¡ect on cell cycle distribution in HeLa cells, in
combination with IR increased the G/M arrested cells up to
80% of the total cell population that lasted for 36 h. These
data indicate that As2O3 delay cell cycle progression after
irradiation. There have been reports suggesting a correlation
between radiosensitivity and G2/M phase delay [18,19]. For
example, a radiosensitive cell line shows longer delay at G2/M
phase than the resistant cell lines upon Q-irradiation [20].
However, it is still possible that the accumulation of cells at
G2/M phase induced by the combined treatment is not a
direct consequence or the primary cause of increased radio-
sensitivity.
Combination of di¡erent anti-tumoral treatment modalities
is advantageous in limiting non-speci¢c toxicity often ob-
served by an exceedingly high dose of single regimen. The
data reported in this study demonstrate that a clinically prom-
ising new anti-cancer drug, As2O3, potentiates the response of
human cervical carcinoma cells to IR both in vitro and in
vivo. As2O3 decreases survival of cancer cells via sensitizing
cells to radiation-induced apoptosis. The apoptosis induced by
the combined treatment in human cervical cancer cells was
associated with loss of mitochondrial membrane potential,
enhanced generation of ROS, and activation of caspase-9
and caspase-3.
Several studies have already demonstrated that As2O3 has
an anti-cancer e¡ect in di¡erent types of cancer cells. Here, we
showed that As2O3 can enhance the e⁄cacy of radiation-in-
duced apoptosis of human cervical cancer cell line. Signi¢-
cantly, the combination of As2O3 and radiation can induce
a complete regression of tumor xenografts established in nude
mice. Taken together, our results indicate that combining ra-
diation and As2O3 may be a new and more e¡ective means of
cancer treatment.
In conclusion, As2O3 in combination with irradiation re-
vealed a synergistic anti-tumoral e¡ect in vitro and in vivo
in human cervical cancer cells, suggesting potential usefulness
of combined therapy of As2O3 together with IR for cervical
cancer treatment.
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